The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma
2 ビュー
• 07/18/23
0
0
埋め込む
administrator
加入者
Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント